Search - tctmd.com

Displaying 161 - 180 of 244

Sort: Relevancy | Date

News Conference News ESC 2018

CLARIFY: No Survival Benefit With Beta-Blockers Beyond 1 Year Post-MI in Stable CAD

Shelley Wood

August 25, 2018

News Daily News

‘Immediate’ Return to Normal Flow Post-PCI in ORBITA-Like Patients

Michael O'Riordan

August 23, 2018

News Daily News

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

Michael O'Riordan

July 31, 2018

News Daily News

ORBITA Redux: Lancet Correspondence Takes Talk of the Sham-Controlled PCI Trial to Further Heights

Michael O'Riordan

July 10, 2018

News Daily News

Norepinephrine Bests Epinephrine in Battle of the Vasopressors in Cardiogenic Shock

L.A. McKeown

July 03, 2018

News Daily News

Once Again, ISCHEMIA Trial Feels the Squeeze

Michael O'Riordan

June 29, 2018

News Daily News

Liability Reform Changes How Docs Manage Suspected Coronary Artery Disease

Michael O'Riordan

June 07, 2018

News Conference News EuroPCR 2018

ORBITA Deep Dive Highlights Treatment Choices, Social Media, and Ethics

Michael O'Riordan

May 31, 2018

News Conference News EuroPCR 2018

Modest Benefit of PCI Over Medical Therapy in Patients With ‘Grey Zone’ FFR Lesions

Michael O'Riordan

May 23, 2018

News Conference News EuroPCR 2018

FFR-Guided PCI Reduces Risk of Death/MI Compared With Medical Therapy: Pooled Analysis

Michael O'Riordan

May 22, 2018

News Daily News

Silent MI Often Precedes Acute MI, Portends Worse Patient Outcomes

Shelley Wood

April 18, 2018

News Features

ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging

Michael O'Riordan

March 23, 2018

ACC 2018, Day Three: Gout, Hypertension, and Diabetes Dominate Opening Late Breaker

News Conference News ACC 2018

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

Shelley Wood

March 12, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Daily News

High Rate of Clinical Events at 6 Months for Ischemic CVD Patients

Michael O'Riordan

January 19, 2018

News Daily News

Prolonged DAPT Does Not Increase Mortality, Cancer Risk: More Evidence

L.A. McKeown

January 12, 2018

News Features

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Michael O'Riordan

November 27, 2017

News Conference News AHA 2017

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

Todd Neale

November 14, 2017

News Conference News AHA 2017

Circling Back on ORBITA: Sham-Controlled PCI Trial Makes Best of 2017 List

Michael O'Riordan

November 12, 2017

News Daily News

Lesion Complexity and Patient Risk: A Balancing Act for DAPT Duration

Yael L. Maxwell

October 23, 2017

Advertisement

CLARIFY: No Survival Benefit With Beta-Blockers Beyond 1 Year Post-MI in Stable CAD

‘Immediate’ Return to Normal Flow Post-PCI in ORBITA-Like Patients

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

ORBITA Redux: Lancet Correspondence Takes Talk of the Sham-Controlled PCI Trial to Further Heights

Norepinephrine Bests Epinephrine in Battle of the Vasopressors in Cardiogenic Shock

Once Again, ISCHEMIA Trial Feels the Squeeze

Liability Reform Changes How Docs Manage Suspected Coronary Artery Disease

ORBITA Deep Dive Highlights Treatment Choices, Social Media, and Ethics

Modest Benefit of PCI Over Medical Therapy in Patients With ‘Grey Zone’ FFR Lesions

FFR-Guided PCI Reduces Risk of Death/MI Compared With Medical Therapy: Pooled Analysis

Silent MI Often Precedes Acute MI, Portends Worse Patient Outcomes

ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

High Rate of Clinical Events at 6 Months for Ischemic CVD Patients

Prolonged DAPT Does Not Increase Mortality, Cancer Risk: More Evidence

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

Circling Back on ORBITA: Sham-Controlled PCI Trial Makes Best of 2017 List

Lesion Complexity and Patient Risk: A Balancing Act for DAPT Duration

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content